[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Zhongshan Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":596},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,229,0,25,[9,42,64,85,112,138,158,179,199,219,237,264,283,305,329,355,381,405,425,449,473,506,527,546,571],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100644850","aspirin-monotherapy-versus-sequential-warfarin-aspirin-therapy-after-tavr-in-patients-with-pure-aortic-regurgitation-100644850",false,"NCT07677410","Aspirin Monotherapy Versus Sequential Warfarin-Aspirin Therapy After TAVR in Patients With Pure Aortic Regurgitation","Prospective, Multicenter, Randomized Controlled Trial Evaluating the Safety and Efficacy of Different Antithrombotic Therapy Strategies in Patients With Severe Aortic Regurgitation Undergoing Transcatheter Aortic Valve Replacement","AWATAR","Inclusion Criteria:\n\n* Age ≥18 years.\n* Patients with severe aortic regurgitation (AR) who achieve technical success after TAVR using devices specifically indicated for AR (per VARC-3 criteria).\n* Trileaflet aortic valve anatomy.\n* No long-term anticoagulation indication (including but not limited to: atrial fibrillation, mechanical mitral valve prosthesis, deep vein thrombosis, pulmonary embolism, left ventricular thrombus, pulmonary hypertension, or coagulation disorders) as confirmed by the investigator.\n* Signed written informed consent and willingness to comply with randomization, study procedures, and follow-up.\n\nExclusion Criteria:\n\n* Need for oral anticoagulation or dual antiplatelet therapy, or need for oral or intravenous strong CYP3A inhibitors that cannot be paused during the study period.\n* Active pathological bleeding, subdural hematoma, or history of intracranial hemorrhage.\n* Ischemic stroke within 30 days before TAVR.\n* Acute myocardial infarction within 30 days.\n* Severe hepatic insufficiency (cirrhosis, hepatic decompensation).\n* Severe renal insufficiency (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²) or need for renal replacement therapy.\n* Stent implantation (including coronary, carotid, or peripheral arteries) within 12 months before TAVR, or planned stent implantation within 1 year after TAVR.\n* Coronary artery bypass grafting (CABG) within 12 months before TAVR.\n* Allergy, intolerance, or known resistance to aspirin, clopidogrel, or warfarin.\n* Known coagulation disorders or bleeding diathesis (including but not limited to platelet count ≤50,000\u002Fmm³ at screening).\n* Any contraindication to anticoagulation therapy.\n* Prior aortic valve prosthesis (mechanical or bioprosthetic); mitral valve bioprosthesis replacement within 1 year before TAVR; or prior mitral mechanical valve replacement; or prior tricuspid valve replacement.\n* Emergency TAVR with cardiogenic shock manifesting as low cardiac output, vasopressor or respiratory dependence, or mechanical hemodynamic support.\n* Life expectancy \\\u003C1 year (e.g., terminal malignancy).\n* Participation in another investigational drug or device clinical study (patients who have completed the primary endpoint of the study and are currently in long-term follow-up are not excluded).\n* Pregnancy or planned pregnancy, or use of estrogen or estrogen-like drugs (for women with suspected pregnancy, serum or urine human chorionic gonadotropin test must be negative before enrollment).\n* Any other condition deemed by the investigator to be inappropriate for study participation.","ALL","18 Years",{"count":21,"type":22},1172,"ESTIMATED","INTERVENTIONAL",[25],"NA","This multicenter randomized controlled trial evaluates antithrombotic strategies post-TAVR in severe aortic regurgitation patients without long-term anticoagulation. Patients are randomized 1:1 to aspirin 75-100 mg daily for 12 months versus warfarin (INR 2-3) for 6 months followed by aspirin for 6 months. Primary hypothesis: aspirin is superior for bleeding and non-inferior for death\u002Fthrombosis. Primary endpoint is a composite of death, stroke, thrombosis, MI, embolism, and major bleeding at 1 year. Sample size: 1172. Follow-up: 30 days, 6 months, 12 months.",[28],"Aortic Regurgitation Disease","RECRUITING","2026-08-07",{"date":32,"type":33},"2026-08-10","ACTUAL",{"date":35,"type":33},"2026-07-18",{"date":37,"type":22},"2030-07-01",{"name":39,"class":40},"Shanghai Zhongshan Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":41},"100646232","a-prospective-observational-study-using-the-fam-cam-100646232","NCT07694687","A Prospective Observational Study Using the FAM-CAM","Family Involvement in ICU Delirium Assessment: A Prospective Observational Study Using the FAM-CAM","Inclusion Criteria\n\nPatients:\n\n* Aged 18 years or older.\n* Admitted to the ICU for at least 24 hours.\n* Richmond Agitation-Sedation Scale (RASS) score ≥ -3 at the time of enrollment.\n* Provided written informed consent to participate. When patients were unable to provide consent, consent was obtained from their legal surrogates.\n\nFamily Members:\n\n* Aged 18 years or older.\n* Identified as the patient's primary family caregiver.\n* Had visited the patient in the ICU at least once.\n* Were able to understand and communicate in Mandarin.\n* Provided written informed consent and voluntarily agreed to participate.\n\nExclusion Criteria\n\nPatients:\n\n* Persistent coma or deep sedation throughout the ICU stay, defined as Glasgow Coma Scale (GCS) score ≤ 8 or RASS score of -4 or -5.\n* A previously confirmed diagnosis of dementia, a severe psychiatric disorder, or an organic neurological disease.\n* Severe hearing impairment that prevented effective communication or study participation.\n\nFamily Members:\n\n-Significant visual, hearing, or cognitive problems that prevented them from understanding the study procedures or completing the study assessments.",{"count":50,"type":22},330,"OBSERVATIONAL","The goal of this observational study is to learn whether family members can help identify signs of delirium in adult patients who are staying in the intensive care unit. Delirium is a sudden change in attention, thinking, or awareness that can happen during serious illness.\n\nThe main question it aims to answer is:\n\nCan family members notice possible signs of delirium that may not be found during routine ICU delirium screening? Participants will receive their usual medical care. Family members who know the patient well will complete a short delirium assessment called the FAM-CAM after visiting the patient. Nurses will continue to perform routine ICU delirium screening using the ICDSC as part of usual care. The study team will compare the family member's assessment with the nurse's routine assessment to see whether family observations provide additional helpful information.\n\nFamily members may complete the assessment for up to 3 days while the patient is in the ICU.",[54,55,56],"Patients in ICU","Delirium in the Intensive Care Unit","Family","2026-08-06",{"date":32,"type":33},{"date":60,"type":22},"2026-08-01",{"date":62,"type":22},"2027-07-31",{"name":39,"class":40},{"id":65,"slug":66,"hasResults":12,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":4},"100651111","accuracy-of-3d-electrical-impedance-tomography-for-assessing-lung-ventilation-100651111","NCT07756086","Accuracy of 3D Electrical Impedance Tomography for Assessing Lung Ventilation","Accuracy of Three-Dimensional Electrical Impedance Tomography for Assessing Dynamic Regional Lung Ventilation Validated by Four-Dimensional CT: A Prospective Observational Study","Inclusion Criteria:\n\n* Age 18 years or older.\n* Healthy volunteers or patients in the intensive care unit for whom CT imaging is considered necessary based on the treating physician's clinical judgment.\n* Able to cooperate with or undergo simultaneous 4D-CT and 3D-EIT monitoring.\n* Able to provide written informed consent personally or through a legally authorized representative, as applicable.\n\nExclusion Criteria:\n\n* Unable to tolerate or having a contraindication to 4D-CT examination, including pregnancy or severe respiratory distress.\n* Extensive chest skin injury or infection, or any condition preventing placement of the EIT electrode belt.\n* Body size or chest deformity that may substantially limit the quality of EIT or CT data, including chest circumference outside the compatible range of the EIT device.\n* Presence of an implanted electronic device that may interfere with EIT signals, such as a cardiac pacemaker.\n* Unable to complete simultaneous 4D-CT and 3D-EIT monitoring because of significant motion, persistent coughing, poor cooperation, or other technical or clinical reasons.\n* Any other condition that, in the investigator's judgment, makes the individual unsuitable for participation in the study.",true,{"count":73,"type":22},50,"This prospective observational study will evaluate how accurately three-dimensional electrical impedance tomography (3D-EIT) measures the distribution of air in the lungs during breathing when compared with four-dimensional computed tomography (4D-CT).\n\n3D-EIT is a noninvasive, radiation-free imaging method that measures changes in electrical impedance across the chest and can provide continuous information about regional lung ventilation. In this study, 4D-CT will be used as the reference method because it can provide detailed images of changes in the lungs throughout the breathing cycle.\n\nApproximately 50 adults, including healthy volunteers and hospitalized patients who are able to undergo both examinations, will be enrolled at a single center. EIT and CT data will be collected at the same time during stable breathing. Researchers will compare the two methods to determine how closely their measurements of ventilation in different lung regions agree. The study will also explore whether EIT can detect changes in regional ventilation under different breathing conditions.\n\nThe study will not use the research EIT results to make clinical treatment decisions. The findings may support the future use of EIT as a noninvasive, radiation-free method for monitoring regional lung ventilation.",[76],"Pulmonary Ventilation","NOT_YET_RECRUITING","2026-08-04",{"date":32,"type":33},{"date":81,"type":22},"2026-09-01",{"date":83,"type":22},"2027-07-01",{"name":39,"class":40},{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},"100648771","phase-3-efficacy-of-lipoic-acid-on-chronic-ischemic-heart-failure-patients-100648771","NCT07725484","Efficacy of Lipoic Acid on Chronic Ischemic Heart Failure Patients","Lipoic Acid in Chronic Ischemic Heart Failure: Assessment of Reduction in Major Adverse Cardiovascular Events","Inclusion Criteria:\n\n* Aged 18 years or older and younger than 75 years at the time of enrollment.\n* A history of chronic heart failure for more than 3 months, or clinical symptoms of heart failure lasting more than 3 months, diagnosed according to the 2023 European Society of Cardiology guidelines for the diagnosis and treatment of chronic heart failure.\n* Left ventricular ejection fraction (LVEF) of 40% or less, as assessed by echocardiography.\n* A history of acute myocardial infarction more than 3 months prior to enrollment, diagnosed according to the Fourth Universal Definition of Myocardial Infarction.\n* New York Heart Association (NYHA) functional class II to IV, with stable clinical symptoms.\n* Receipt of guideline-directed medical therapy for heart failure for at least 2 weeks, without dose adjustment or intravenous therapy during this period. Guideline-directed medical therapy includes: Angiotensin-converting enzyme inhibitors (ACEIs), or Angiotensin receptor blockers (ARBs), or Angiotensin receptor-neprilysin inhibitors (ARNIs), Beta-blockers, and Mineralocorticoid receptor antagonists,unless contraindicated or not tolerated, and prescribed at optimal tolerated doses.\n* Ability and willingness to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Prior cardiac resynchronization therapy (CRT).\n* Severe hepatic dysfunction, defined as liver transaminase levels greater than three times the upper limit of normal, or severe renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) less than 30 mL\u002Fmin\u002F1.73 m².\n* Presence of uncontrolled malignant arrhythmias or progressively worsening unstable angina.\n* Presence of malignancy, lymphoma, leukemia, or other serious diseases with an expected life expectancy of less than 1 year.\n* Participation in another investigational drug study within 4 weeks prior to enrollment, or current receipt of any investigational treatment other than the study intervention.\n* Pregnant or breastfeeding women.\n* Known allergy to vitamin B-related medications.","75 Years",{"count":94,"type":22},1526,[96],"PHASE3","Chronic heart failure is a clinical condition caused by structural heart disease and is characterized by reduced pumping function, fluid retention, and abnormal activation of neurohormonal systems. It represents the advanced stage of many cardiovascular diseases and remains a major global health challenge. Despite progress in medical and interventional therapies, patients with chronic heart failure continue to experience high rates of death, hospitalization, and long-term disability.\n\nIschemic heart failure, which develops as a result of coronary artery disease and prior myocardial infarction, is the most common form of chronic heart failure. Current treatment strategies, including guideline-directed medical therapy and revascularization procedures, can improve symptoms and outcomes but do not fully address the residual risk of adverse cardiovascular events. Therefore, additional therapeutic approaches are needed to further improve long-term prognosis in this population.\n\nAbnormal myocardial energy metabolism is a key pathological feature of heart failure. Mitochondria play a central role in energy production, and impaired mitochondrial function contributes to disease progression. Previous studies by our group have identified mitochondrial aldehyde dehydrogenase 2 (ALDH2) as an important regulator of myocardial metabolic homeostasis and cardiac protection under ischemic and stress conditions.\n\nAlpha-lipoic acid is a vitamin B-related compound with antioxidant properties and has been widely used in clinical practice for other indications. Increasing evidence suggests that alpha-lipoic acid may also exert protective effects in cardiovascular diseases, potentially through modulation of mitochondrial function. Experimental studies have shown that alpha-lipoic acid can restore ALDH2 activity and improve cardiac function in models of heart failure.\n\nBased on these findings, we conducted an exploratory randomized controlled trial between 2019 and 2023 to evaluate the safety and potential efficacy of alpha-lipoic acid in patients with ischemic heart failure. In this multicenter study, patients receiving alpha-lipoic acid showed favorable trends toward reduced risk of death and heart failure-related hospitalization, as well as significant improvements in left ventricular ejection fraction and exercise capacity, without an increase in adverse events.\n\nTaken together, prior mechanistic research and early clinical evidence support the hypothesis that alpha-lipoic acid may provide additional benefit when used as adjunctive therapy in patients with chronic ischemic heart failure. The present study is designed to further evaluate whether long-term supplementation with alpha-lipoic acid can reduce major adverse cardiovascular events and improve clinical outcomes in this population.",[99],"Heart Failure Due to Coronary Artery Disease",[101,102,103],"alpha lipoic acid","major adverse cardiovascular events","Ischemic heart failure",{"date":105,"type":33},"2026-08-05",{"date":107,"type":22},"2026-11-01",{"date":109,"type":22},"2030-12-01",{"name":39,"class":40},21,{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":123,"conditions":124,"keywords":127,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":41},"100643534","phase-2-a-phase-ii-study-to-evaluate-the-efficacy-and-safety-of-teclistamab-in-combination-with-daratumumab-tec-dara-in-newly-diagnosed-multiple-myeloma-with-concurrent-light-chain-amyloidosis-mmal-100643534","NCT07638683","A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).","A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL)","Inclusion Criteria:\n\n1. Age ≥18 years, any sex\u002Fgender\n2. Diagnosis of multiple myeloma according to IMWG criteria\n3. Histopathologic diagnosis of AL amyloidosis confirmed by:\n\n   * Green birefringence under polarized light microscopy with Congo red staining; AND at least one of the following:\n\n     1. Immunohistochemistry and\u002For immunofluorescence\n     2. Mass spectrometry\n     3. Electron microscopy\u002Fimmunoelectron microscopy\n4. Measurable disease at screening\n5. Newly diagnosed, no prior anti-plasma cell therapy\n6. Adequate laboratory values:\n\n   * Hemoglobin ≥7.5 g\u002FdL\n   * Absolute neutrophil count ≥1.0×10⁹\u002FL\n   * Platelet count ≥70×10⁹\u002FL (platelet transfusion acceptable; \\>50×10⁹\u002FL if ≥50% bone marrow nucleated cells are plasma cells)\n   * ALT ≤2.5× upper limit of normal (ULN)\n   * AST ≤2.5× ULN\n   * Total bilirubin ≤2.0× ULN\n   * Creatinine clearance ≥30 mL\u002Fmin\n   * Corrected serum calcium ≤14 mg\u002FdL\n7. Male and female participants of childbearing potential must use at least 2 effective contraceptive methods during the study\n8. Voluntarily signed informed consent form (ICF)\n\nExclusion Criteria:\n\n1. Prior anti-myeloma therapy or stem cell transplantation\n2. Diagnosis of monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma, primary AL amyloidosis without concurrent MM, Waldenström macroglobulinemia, plasma cell leukemia, POEMS syndrome, or other malignancies within 3 years prior to enrollment\n3. Active infection or autoimmune disease\n4. Uncontrolled diabetes, hypertension, or other comorbidities\n5. Pregnant or lactating female\n6. Currently participating in another interventional study\n7. Any other condition that the investigator considers unsuitable for study participation",{"count":120,"type":22},30,[122],"PHASE2","The goal of this clinical trial is to learn if teclistamab in combination with daratumumab (Tec-Dara) works to treat newly diagnosed multiple myeloma with concurrent light chain amyloidosis (MM+AL). It will also learn about the safety of this combination. The main questions it aims to answer are:\n\nDoes Tec-Dara improve the 1-year progression-free survival rate compared to historical data (50% to 75%) in MM+AL patients? What are the rates of hematologic response (ORR, VGPR, CR, MRD negativity) and organ response in MM+AL patients treated with Tec-Dara? What medical problems do participants have when taking Tec-Dara?\n\nParticipants will:\n\nReceive teclistamab subcutaneous injection with step-up dosing (0.06, 0.3, 1.5 mg\u002Fkg), followed by 1.5 mg\u002Fkg weekly in Cycle 1, 3.0 mg\u002Fkg every 2 weeks in Cycles 2-3, and 3.0 mg\u002Fkg every 4 weeks in Cycles 4-24 Receive daratumumab subcutaneous injection 1800 mg weekly in Cycles 1-2, every 2 weeks in Cycles 3-6, and every 4 weeks in Cycles 7-24 Continue treatment until disease progression, unacceptable toxicity, or a maximum of 24 cycles Undergo disease assessments every 28 days (±7 days) including laboratory tests for hematologic and organ response evaluation Provide bone marrow samples for MRD and RNA sequencing analysis",[125,126],"Multiple Myeloma","AL Amyloidosis",[125,126,128,129],"Teclistamab","Daratumumab","2026-07-30",{"date":132,"type":33},"2026-08-03",{"date":134,"type":33},"2026-05-22",{"date":136,"type":22},"2028-12-30",{"name":39,"class":40},{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":18,"minAge":145,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":152,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":41},"100574497","longitudinal-data-registry-of-plasma-cell-dyscrasia-100574497","NCT06760052","Longitudinal Data Registry of Plasma Cell Dyscrasia","Longitudinal Data Registry of A Spectrum of Plasma Cell Dyscrasia With Long-term Follow-up","Inclusion Criteria:\n\n* Patients with pathological diagnosis of PCD \\[e.g., symptomatic\u002Fasymptomatic multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), POEMS syndrome, light chain (AL) amyloidosis\\] from 2007 to 2027 in Zhongshan Hospital or other collaborating centers.\n* Patients who had complete diagnostic, treatment, and follow-up records.\n* Patients with full comprehension and signature of the informed consent form (ICF) for participation.\n\nExclusion Criteria:\n\n* Patients who refused to use reliable methods of contraception during pregnancy, lactation, or the age-appropriate period.\n* Patients who suffered from severe mental illness.\n* Patients who were deemed unsuitable for inclusion by the investigator.","19 Years","99 Years",{"count":148,"type":22},2000,"The goal of this multicenter observational study is to better understand the clinical and molecular characteristics, disease progression, treatment response, and clinical outcomes of patients with plasma cell dyscrasias, including monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, and light-chain amyloidosis. The study is led by Zhongshan Hospital, Fudan University, in collaboration with 18 other research centers in China. The main questions it aims to answer are:\n\nWhich clinical, laboratory, pathological, immunologic, cytogenetic, and genomic characteristics are associated with disease progression, treatment response, and patient outcomes? How do plasma cell dyscrasias and their underlying clones evolve over time? Can clinical and molecular information be used to develop models that predict disease progression and patient outcomes?\n\nResearchers will collect and analyze historical and prospective clinical data from participating centers and follow patients over time. Participants' clinical course, laboratory and other test results, treatments, disease progression, and outcomes will be recorded and analyzed. This is an observational study and does not assign participants to any specific treatment.",[151],"Multiple Myeloma and Other Plasma Cell Neoplasms",{"date":132,"type":33},{"date":154,"type":33},"2023-03-01",{"date":156,"type":22},"2028-12-31",{"name":39,"class":40},{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":4},"100649371","linematrix-biological-vascular-graft-for-infra-renal-arterial-bypass-or-replacement-100649371","NCT07733076","LineMatrix® Biological Vascular Graft for Infra-renal Arterial Bypass or Replacement","A Preliminary Study to Evaluate the Safety and Efficacy of LineMatrix® Biological Vascular Graft for Infra-renal Arterial Bypass or Replacement","Inclusion Criteria:\n\n* 1.Adults aged ≥18 and ≤80 years, inclusive;\n* 2.Patients evaluated by the investigative staff as requiring infra-renal arterial bypass or arterial replacement, including but not limited to: ischemia, infection, trauma, arterial rupture;\n* 3.For ischemic limbs requiring infra-inguinal arterial bypass, Rutherford stage 3-6; Ankle-Brachial Index (ABI) ≤0.6; Preoperative imaging showing at least one below-knee artery vessel patent to the ankle with good runoff; No whole-segment healthy great saphenous vein available;\n* 4.Patients who are able to communicate effectively with investigative staff, competent and willing to give written informed consent, and are able to comply with entire study procedures including all scheduled follow-up visits.\n\nExclusion Criteria:\n\n* 1.Distal target artery diameter \\\u003C2.5mm;\n* 2.Known or suspected allergy to contrast media, anticoagulant\u002Fantiplatelet drugs, alcohol, or bovine-derived products;\n* 3.Hemoglobin \\\u003C60g\u002FL, platelet count \\\u003C60×10⁹\u002FL;\n* 4.Left ventricular ejection fraction \\\u003C30%;\n* 5.Severe cardiac disease: including New York Heart Association (NYHA) Scale III-IV severe heart failure, or a history of myocardial infarction, ventricular tachyarrhythmias requiring continuing treatment, or unstable angina within 3 months;\n* 6.Stroke within 3 months prior to study entry;\n* 7.Uncontrolled or poorly controlled diabetes (preoperative glycated hemoglobin \\>10%);\n* 8.Active inflammatory vascular disease;\n* 9.Patients with autoimmune diseases or currently receiving immunosuppressive drug therapy;\n* 10.Active malignancy or other severe systemic disease with life expectancy less than 12 months;\n* 11.History of heparin-induced thrombocytopenia type II (HIT-II) or other contraindications to heparin use;\n* 12.AST or ALT \\>2× the upper limit of normal;\n* 13.Coagulation abnormalities (APTT or PT \\>1.5× upper limit of normal);\n* 14.Severe psychiatric disorders that interfere with study compliance;\n* 15.Pregnant or breastfeeding female, intending to become pregnancy, or could not use a highly effective method of birth control during the study period;\n* 16.Patients in another drug or medical device clinical trials has not yet been enrolled before enrollment;\n* 17.There are other factors that deemed unsuitable for study participation by the investigator.","80 Years",{"count":167,"type":22},15,[25],"Single center, single arm study to evaluate the Safety and Efficacy of LineMatrix® Biological Vascular Graft for Infra-renal Arterial Bypass or Replacement",[171],"Peripheral Arterial Disease","2026-07-28",{"date":130,"type":33},{"date":175,"type":22},"2026-09-30",{"date":177,"type":22},"2028-09-30",{"name":39,"class":40},{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":165,"enrollmentInfo":186,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":4},"100649353","peripheral-blood-biomarkers-and-response-to-atezolizumab-plus-bevacizumab-in-hepatocellular-carcinoma-100649353","NCT07734857","Peripheral Blood Biomarkers and Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma","Peripheral Blood Biomarkers for Predicting Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: A Single-Center Prospective Observational Cohort Study","Inclusion Criteria:\n\n* Age 18-80 years\n* Histologically or clinically confirmed unresectable or advanced HCC, classified according to the BCLC staging system\n* Planned to receive first-line atezolizumab plus bevacizumab therapy, with no prior systemic therapy for unresectable or advanced HCC\n* At least one measurable target lesion with a longest diameter of ≥10 mm on CT or MRI according to RECIST 1.1, with mRECIST assessment performed when applicable\n* Availability of baseline and follow-up clinical and radiological data\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Presence of another active malignancy, except for malignancies that have been curatively treated and remain recurrence-free\n* Prior systemic treatment with immune checkpoint inhibitors or anti-angiogenic agents for unresectable or advanced HCC\n* Expected inability to complete the required clinical or radiological follow-up assessments\n* Severe comorbid conditions that may interfere with study participation\n* No qualified residual blood sample available for planned biomarker analyses because of insufficient volume, contamination, loss, or other sample-related issues\n* Any condition deemed unsuitable for participation by the investigator",{"count":187,"type":22},100,"This single-center prospective observational cohort study aims to evaluate the predictive value of peripheral blood-based biomarkers for treatment response in patients with hepatocellular carcinoma (HCC) receiving first-line atezolizumab plus bevacizumab (T+A) therapy. Residual peripheral blood samples obtained during routine clinical testing will be analyzed without additional blood draws. The study hypothesizes that baseline and longitudinal peripheral blood biomarkers are associated with treatment response and can be used to identify patients more likely to benefit from T+A therapy. Treatment response will be evaluated based on the best overall response (BOR) during treatment. The primary efficacy assessment will be performed according to RECIST 1.1, while modified RECIST (mRECIST) will be used as a supportive assessment. Predictive models based on peripheral blood biomarkers will be developed using RECIST 1.1-defined treatment response as the primary analysis, with mRECIST used for supportive and sensitivity analyses.",[190],"Hepatocellular Carcinoma (HCC)","2026-07-27",{"date":193,"type":33},"2026-07-29",{"date":195,"type":22},"2026-07-10",{"date":197,"type":22},"2028-07-30",{"name":39,"class":40},{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":23,"phases":207,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":4},"100649436","impact-of-3d-eit-guided-acapella-breathing-training-on-lung-ventilation-distribution-100649436","NCT07733843","Impact of 3D-EIT-Guided Acapella Breathing Training on Lung Ventilation Distribution","Impact of Visualized 3D-EIT-Guided Acapella Breathing Training on Lung Ventilation Distribution: A Prospective Single-Center Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥18 years.\n* Adult patients in the stable recovery phase following critical illness, breathing spontaneously, alert, and able to follow instructions (suggested Richmond Agitation-Sedation Scale \\[RASS\\] score of -1 to +1).\n* Hemodynamically stable, with no vasopressor support or only a low and stable dose of vasopressors.\n* Receiving stable low-flow oxygen therapy or equivalent non-escalating respiratory support, without an anticipated need for escalation in the short term.\n* Clinically considered suitable for standardized Acapella breathing exercises.\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Significant hemodynamic instability or clinically significant cardiac arrhythmia.\n* Untreated pneumothorax or active hemoptysis.\n* Severe chest wall skin injury or allergy to electrode materials that prevents application of the electrical impedance tomography electrodes.\n* Significant delirium or inability to understand or follow study instructions.\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in the study.",{"count":120,"type":22},[25],"The goal of this randomized clinical trial is to determine whether real-time visual feedback from three-dimensional electrical impedance tomography (3D-EIT) can improve the effects of Acapella breathing exercises in adults recovering from critical illness. 3D-EIT is a noninvasive bedside imaging method that provides real-time information about how ventilation is distributed within the lungs.\n\nParticipants will be randomly assigned to one of two groups. Both groups will perform a standardized Acapella breathing exercise while 3D-EIT data and vital signs are recorded. Participants in the control group will receive routine verbal and demonstration-based breathing instructions without viewing the EIT images. Participants in the intervention group will receive the same instructions and will also view their own real-time 3D-EIT ventilation images. They will use this visual feedback to adjust their breathing with the goal of increasing ventilation in the dorsal regions of the lungs and\u002For achieving a more even distribution of ventilation.\n\nThe main question is whether 3D-EIT-guided visual feedback results in a greater improvement in end-expiratory lung impedance (EELI) after breathing exercise compared with routine instruction alone. The study will also examine changes in regional ventilation distribution, ventilation inhomogeneity, vital signs, breathing discomfort, comfort and tolerance, achievement of the breathing-training target, and adverse events.\n\nApproximately 30 participants will be enrolled and randomly assigned in a 1:1 ratio to the two study groups.",[210,211],"Critical Illness Recovery","Pulmonary Rehabilitation","2026-07-25",{"date":193,"type":33},{"date":215,"type":22},"2026-07-31",{"date":217,"type":22},"2027-03-21",{"name":39,"class":40},{"id":220,"slug":221,"hasResults":12,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":228,"conditions":229,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":232,"completionDateStruct":233,"leadSponsor":235,"locationsCount":236},"100648744","the-efficacy-and-safety-of-donafenib-plus-pd-1l1-monoclonal-antibodies-plus-tace-or-haic-as-first-line-treatment-for-unresectable-hepatocellular-carcinoma-a-multi-center-retrospective-clinical-study-100648744","NCT07724951","The Efficacy and Safety of Donafenib Plus PD-1\u002FL1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study","The Efficacy and Safety of Donafenib Plus PD-1\u002FL1 Monoclonal Antibodies Plus Transarterial Chemoembolization (TACE) or Hepatic Arterial Infusion Chemotherapy (HAIC) as First-line Treatment for Unresectable Hepatocellular carcinomaA Multicenter, Retrospective Clinical Study","Inclusion Criteria:\n\n* Patients with unresectable hepatocellular carcinoma (uHCC) who received donafenib, an anti-PD-1\u002FL1 monoclonal antibody combined with transarterial interventional therapy (TACE or HAIC), with retrievable records in the hospital electronic information system between June 1, 2021 and November 30, 2024.\n* Diagnosis of hepatocellular carcinoma confirmed by the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 Edition) clinically or by histology\u002Fcytology.\n* Age ≥18 years, regardless of sex.\n* No prior systemic therapy before the administration of donafenib, anti-PD-1\u002FL1 monoclonal antibody combined with transarterial interventional therapy (TACE or HAIC).\n* The maximum interval between the initiation of donafenib, anti-PD-1\u002FL1 monoclonal antibody, and transarterial interventional therapy (TACE or HAIC) does not exceed 8 weeks, and at the time the last of these treatment modalities is initiated, the subject must not have experienced disease progression.\n* For patients who have previously undergone hepatectomy, the resection must be R0, and tumor recurrence must have occurred more than 24 months after surgery.\n* At least one evaluable lesion (according to RECIST v1.1 criteria).\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 to 1.\n* Child-Pugh class A or B.\n* Adequate major organ function, defined by the following criteria:\n\nComplete blood count (without blood transfusion or use of granulocyte colony-stimulating factor \\[G-CSF\\] within 14 days prior to screening):\n\n1. Hemoglobin ≥90 g\u002FL;\n2. Absolute neutrophil count (ANC) ≥1.5×10⁹\u002FL;\n3. Platelet count ≥75×10⁹\u002FL;\n\n   \\- Blood biochemistry (without albumin use within 14 days prior to screening):\n4. Albumin ≥28 g\u002FL;\n5. Total bilirubin ≤2× upper limit of normal (ULN);\n6. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤5× ULN;\n7. Alkaline phosphatase (ALP) ≤5× ULN;\n8. Creatinine ≤1.5× ULN;\n\n   \\- Coagulation function:\n9. International normalized ratio (INR) or prothrombin time (PT) ≤1.5× ULN;\n10. Activated partial thromboplastin time (APTT) ≤1.5× ULN.\n\nExclusion Criteria:\n\n* Incomplete or unavailable patient information data; patient refused follow-up or was lost to follow-up;\n* Duration of donafenib, PD-1\u002FL1 monoclonal antibody combined with transarterial intervention therapy was less than 1 month;\n* Prior histologically\u002Fcytologically confirmed diagnosis of fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma, or other components;\n* History of malignancy other than hepatocellular carcinoma, unless meeting the following criteria: a) The patient received potentially curative treatment and there has been no evidence of disease for 5 years; b) Successfully treated resected cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ, or other carcinoma in situ;",{"count":227,"type":22},400,"This is a multicenter, retrospective study planned to enroll patients with unresectable hepatocellular carcinoma (uHCC) who received first-line donafenib combined with an anti-PD-1\u002FL1 monoclonal antibody and either TACE or HAIC at 8 sites between June 1, 2021 and November 30, 2024. The study consists of two cohorts: Cohort A consists of patients who received donafenib + PD-1\u002FL1 inhibitor + TACE, and Cohort B consists of patients who received donafenib + PD-1\u002FL1 inhibitor + HAIC, with a planned enrollment of 200 patients per cohort. Relevant data will be collected to evaluate the efficacy and safety of donafenib combined with an anti-PD-1\u002FL1 monoclonal antibody and either TACE or HAIC in the treatment of uHCC in real-world clinical practice.",[190],"2026-07-24",{"date":191,"type":33},{"date":215,"type":22},{"date":234,"type":22},"2028-07-31",{"name":39,"class":40},8,{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":92,"enrollmentInfo":244,"targetDuration":4,"studyType":23,"phases":246,"briefSummary":247,"conditions":248,"keywords":250,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":41},"100649416","phase-2-ql1706iparomlimabtuvonralimab-combined-with-gemcitabine-and-cisplatin-as-first-line-treatment-for-pd-l1-positive-biliary-tract-cancer-100649416","NCT07733115","QL1706（Iparomlimab\u002FTuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer","A Multicenter, Single-Arm, Phase II Clinical Study of QL1706 in Combination With Gemcitabine and Cisplatin (GC) as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer","Inclusion Criteria:\n\n1. Have signed the written informed consent form and be able to comply with all scheduled visits and study procedures specified in the protocol.\n2. Aged between 18 and 75 years old (inclusive), with no restriction on gender.\n3. Histologically confirmed unresectable or metastatic advanced biliary tract adenocarcinoma, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer.\n4. PD-L1-positive tumor (Combined Positive Score \\[CPS\\] ≥ 1).\n5. Have at least one measurable lesion per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).\n6. No prior systemic therapy (chemotherapy, targeted therapy, or immunotherapy). Patients who relapse more than 6 months after curative surgery, and if they have received adjuvant therapy (chemotherapy and\u002For radiotherapy), relapse more than 6 months after completion of adjuvant therapy, are eligible.\n7. Life expectancy of at least 12 weeks.\n8. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.\n9. Have adequate organ and bone marrow function. Laboratory test results obtained within 7 days prior to enrollment shall meet the following requirements. No blood products, erythropoietin, colony-stimulating factors, thrombopoietin, albumin or other parenteral corrective medications are allowed within 14 days before laboratory testing:\n\n   * Hematology: Absolute Neutrophil Count (ANC) ≥ 1.5×10⁹\u002FL; Platelet (PLT) count ≥ 100×10⁹\u002FL; Hemoglobin (HGB) \\> 9 g\u002FdL.\n   * Liver function: Total Bilirubin (TBIL) ≤ 1.5 × Upper Limit of Normal (ULN); Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2.5 × ULN.\n   * Renal function: Creatinine clearance (calculated by the Cockcroft-Gault formula) ≥ 60 mL\u002Fmin.\n   * Thyroid function: Thyroid-stimulating hormone (TSH) within normal range. If baseline TSH is outside normal range, patients are eligible if total T3 (or FT3) and FT4 are within normal limits.\n   * Cardiac enzymes: Within normal limits (isolated laboratory abnormalities deemed clinically insignificant by the investigator are allowed).\n10. Female participants of childbearing potential and male participants whose partners are of childbearing potential must agree to use effective contraception throughout the treatment period and for 6 months after the last study drug administration.\n\nExclusion Criteria:\n\n1. Histologically or cytologically confirmed diagnosis of tumors containing components other than biliary adenocarcinoma (e.g., neuroendocrine carcinoma, squamous cell carcinoma, or mixed histologies).\n2. Prior treatment with anti-PD-1\u002FPD-L1 agents, anti-CTLA-4 agents, or other antitumor immunotherapies.\n3. Presence of unresolved Grade \\>1 toxicities related to any previous antitumor therapy (persistent Grade 2 alopecia, fatigue, or endocrine disorders well-controlled with hormone replacement therapy are excluded).\n4. History of other malignancies within 5 years prior to enrollment, except for radically cured basal cell carcinoma, squamous cell carcinoma of the skin, carcinoma in situ with no evidence of recurrence, or other malignancies with complete remission and no active disease for at least 2 years prior to enrollment.\n5. Active autoimmune disease requiring systemic treatment (e.g., disease-modifying drugs, corticosteroids, or immunosuppressants) within 2 years prior to the first drug administration. Replacement therapies (e.g., levothyroxine, insulin, physiological corticosteroids for adrenal or pituitary insufficiency) are not regarded as systemic treatment. Known primary immunodeficiency. Patients with positive autoantibodies only should be assessed by the investigator for the presence of autoimmune disease.\n6. Systemic corticosteroid therapy (excluding nasal, inhaled, or other topical corticosteroids) or any other form of immunosuppressive therapy within 4 weeks prior to first dose. Note: Physiologic doses of corticosteroids (≤ 10 mg\u002Fday of prednisone or equivalent) are permitted.\n7. Clinically uncontrolled pleural effusion or ascites (patients who do not require drainage or have no significant increase in fluid for 3 days after drainage cessation may be enrolled).\n8. Known allogeneic organ transplant (except corneal transplant) or allogeneic hematopoietic stem cell transplant.\n9. Known allergy to any active ingredient or excipient of the study drugs.\n10. Presence of clinically significant cardiovascular and cerebrovascular diseases, including:\n\n    * Electrocardiogram abnormalities (e.g., complete left bundle branch block, second-degree or higher heart block, ventricular arrhythmias, or atrial fibrillation) that are symptomatic and difficult to control.\n    * Unstable angina, congestive heart failure, or chronic heart failure of New York Heart Association (NYHA) Class ≥ 2.\n    * Any arterial thrombotic, embolic, or ischemic event (e.g., myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack) within 6 months prior to enrollment.\n    * Uncontrolled hypertension (systolic blood pressure \\> 140 mmHg, diastolic blood pressure \\> 90 mmHg).\n11. Major surgical procedure (craniotomy, thoracotomy, or laparotomy) within 4 weeks prior to first dose, or non-healing wounds, ulcers, or fractures.\n12. Active tuberculosis; patients currently receiving anti-tuberculosis treatment or those who received anti-tuberculosis therapy within 1 year before the first drug administration.\n13. Active or uncontrolled infection requiring systemic treatment.\n14. Clinically active diverticulitis, abdominal abscess, or gastrointestinal obstruction.\n15. Poorly controlled diabetes (fasting blood glucose \\> 10 mmol\u002FL).\n16. Urinalysis showing protein ≥ 2+ with 24-hour urine protein \\> 1.0 g.\n17. Confirmed HIV positivity or history of acquired immunodeficiency syndrome (AIDS).\n18. Untreated active hepatitis B (defined as HBsAg positive with HBV-DNA copy number \\> 2000 IU\u002FmL); patients with HBV-DNA positive may be enrolled if levels show a declining trend.\n19. Active HCV infection (HCV antibody positive and HCV-RNA above the lower limit of detection).\n20. Vaccination with live attenuated vaccine within 4 weeks prior to first dose.\n21. Pregnant or breastfeeding females, or females planning to become pregnant before drug administration, during treatment or within 6 months after the last dose of study drug.\n22. Psychiatric disorders preventing treatment compliance.\n23. Any concomitant disease, prior treatment, abnormal laboratory findings, history of substance abuse or current substance use, which in the investigator's judgment may compromise patient safety, hinder informed consent acquisition, affect treatment compliance or interfere with the safety assessment of the study drug.",{"count":245,"type":22},38,[122],"The goal of this clinical trial is to evaluate whether QL1706(Iparomlimab\u002FTuvonralimab) in combination with gemcitabine and cisplatin (GC) is effective and safe as a first-line treatment for patients with advanced biliary tract cancer whose tumors are PD-L1 positive (CPS ≥ 1). This is a multicenter, single-arm, phase II clinical study. A total of 38 eligible patients will be enrolled .\n\nThe main questions it aims to answer are: what proportion of patients achieve objective response (tumor shrinkage) after receiving QL1706 plus GC, as measured by the objective response rate (ORR)? How long do the treatment benefits last, in terms of disease control rate (DCR), duration of response (DOR), time to response (TTR), progression-free survival (PFS), and overall survival (OS)? What is the safety profile of QL1706 combined with GC, including the frequency and severity of adverse events, treatment-related adverse events, serious adverse events, and immune-related adverse events? Participants will receive QL1706 (5 mg\u002Fkg, intravenous infusion) once every 3 weeks in combination with gemcitabine (1000 mg\u002Fm² on days 1 and 8) and cisplatin (25 mg\u002Fm² on days 1 and 8) for up to 8 cycles (each cycle is 3 weeks), and after completing 8 cycles of combination therapy, they will continue QL1706 alone as maintenance therapy (5 mg\u002Fkg once every 3 weeks) until disease progression, unacceptable toxicity, withdrawal of consent, loss to follow-up, death, or completion of 2 years of treatment, whichever occurs first. Participants will undergo tumor imaging assessments (using CT or MRI) every 9 weeks (±7 days) during the treatment period, with responses evaluated . Participants will also have regular blood tests, physical examinations, electrocardiograms, and other safety assessments at each treatment cycle, and will provide tumor tissue and blood samples before treatment and at various time points during the study for biomarker analyses to explore correlations with treatment response. Finally, participants will be followed for adverse events for 30 days after the last dose, for serious adverse events for 90 days after the last dose, and for survival status every 90 days (±14 days) after the end of treatment until death, study completion, or loss to follow-up.\n\nThe study is expected to provide valuable evidence on whether the addition of QL1706 to standard GC chemotherapy offers a new treatment option for patients with PD-L1-positive advanced biliary tract cancer, and to identify potential biomarkers that may help predict which patients are most likely to benefit from this combination therapy.",[249],"Biliary Tract Cancer (BTC)",[251,252,253,254,255,256],"Biliary Tract Cancer","Immunotherapy","Iparomlimab","Gemcitabine","Cisplatin","Tuvonralimab","2026-07-23",{"date":193,"type":33},{"date":260,"type":22},"2026-07-20",{"date":262,"type":22},"2029-12-31",{"name":39,"class":40},{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":23,"phases":272,"briefSummary":273,"conditions":274,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":4},"100648868","evaluate-the-diagnostic-efficacy-and-safety-of-inr-202-petct-imaging-in-participants-with-advanced-solid-tumors-100648868","NCT07727317","Evaluate the Diagnostic Efficacy and Safety of INR 202 PET\u002FCT Imaging in Participants With Advanced Solid Tumors","A Clinical Study to Evaluate the Diagnostic Efficacy and Safety of INR 202 PET\u002FCT Imaging in Participants With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. ECOG performance status of 0 or 1.\n3. Advanced solid tumors.\n4. Adequate organ functions.\n5. Life expectancy ≥6 months.\n6. Agreement to use contraceptive measures from the date of informed consent signing until 3 months after administration of INR202, and to avoid sperm or egg donation during this period.\n7. The participant (or legal guardian, where applicable) is fully informed of the purpose and procedures of the study, is able to understand the information provided, and voluntarily signs the informed consent form.\n\nExclusion Criteria:\n\n1. Unable to complete imaging examinations as required by the study protocol, in the investigator's judgement.\n2. With a history of ≥2 malignancies within 5 years prior to administration of INR202, except for adequately treated non-metastatic thyroid cancer, basal cell carcinoma of the skin, superficial squamous cell carcinoma of the skin, or superficial bladder cancer.\n3. Known hypersensitivity to the active ingredient of INR202 or any of its components.\n4. Any medical condition or other situation that, in the investigator's judgement, may affect safety, compliance, or study outcomes.",{"count":120,"type":22},[25],"This is a prospective, single-center, open-label clinical study comparing the imaging performance of INR202 PET\u002FCT versus 18F-FDG PET\u002FCT in participants with advanced solid tumors.",[275],"Solid Tumors","2026-07-22",{"date":191,"type":33},{"date":279,"type":22},"2026-08",{"date":281,"type":22},"2028-07",{"name":39,"class":40},{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":92,"enrollmentInfo":289,"targetDuration":4,"studyType":23,"phases":291,"briefSummary":293,"conditions":294,"keywords":296,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":301,"completionDateStruct":302,"leadSponsor":304,"locationsCount":4},"100647835","phase-1-phase-ibii-multicenter-randomized-control-study-of-peri-operative-treatment-with-combination-of-ctla-4-pd-1-antibodies-and-bevacizumab-in-resectable-hcc-prophet-100647835","NCT07714317","Phase Ib\u002FII Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)","Inclusion Criteria:\n\n1. Written informed consent shall be obtained prior to any trial-related procedures.\n2. Male or female patients aged ≥18 years and ≤75 years.\n3. Initial resectable hepatocellular carcinoma (HCC) confirmed by imaging, pathology or cytology.\n4. No macrovascular tumor thrombus or extrahepatic metastasis detected on imaging examinations.\n5. Single intrahepatic tumor \\>5 cm in diameter, or 2-3 intrahepatic tumors with no restriction on tumor diameter (corresponding to CNLC stage Ib-IIa of primary liver cancer in China).\n6. The maximum tumor diameter \\\u003C 8 cm.\n7. Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.\n8. Child-Pugh Class A liver function.\n9. No prior systemic therapy or locoregional therapy for HCC; patients with recurrence ≥2 years after previous curative surgical resection or ablation are eligible for enrollment.\n10. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).\n11. Adequate organ function.\n\nExclusion Criteria:\n\n1. Histologically or cytologically confirmed tumors containing components of fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma, or other mixed subtypes.\n2. History of hepatic encephalopathy or prior liver transplantation.\n3. Currently participating in an interventional clinical trial, or received any investigational medicinal product or investigational device within 4 weeks prior to the first study drug administration.\n4. Prior receipt of any of the following therapies: anti-PD-1, anti-PD-L1, anti-PD-L2 agents, or agents targeting other T-cell co-stimulatory or co-inhibitory receptors (including but not limited to CTLA-4, OX-40, CD137).\n5. Received systemic therapy with Chinese patent medicines with anti-tumor indications or immunomodulatory agents (including thymopeptides, interferons, interleukins; excluding local intrapleural administration for controlling pleural effusion) within 2 weeks prior to the first study drug administration.\n6. History of active autoimmune disease requiring systemic therapy (e.g., disease-modifying agents, corticosteroids, immunosuppressants) within 2 years before the first study drug administration. Replacement therapies (e.g., thyroxine, insulin, physiologic corticosteroids for adrenal or pituitary insufficiency) shall not be regarded as systemic treatment.\n7. Receiving systemic corticosteroid therapy (excluding intranasal, inhaled, or other locally administered corticosteroids) or any other form of immunosuppressive therapy within 7 days prior to the first study drug administration.\n\n   Note: Physiologic doses of corticosteroids (≤10 mg prednisone equivalent per day) are permitted.\n8. Known history of allogeneic solid organ transplantation (excluding corneal transplantation) or allogeneic hematopoietic stem cell transplantation.\n9. Known hypersensitivity to any study drug used in this trial.\n10. Have not fully recovered from toxicities and\u002For complications induced by any prior intervention before study treatment initiation.\n11. Known history of human immunodeficiency virus (HIV) infection.\n12. Untreated active hepatitis B virus (HBV) infection.\n13. Subjects with active hepatitis C virus (HCV) infection.\n14. Received any live vaccine within 30 days prior to the first study drug administration (Day 1 of Cycle 1).\n15. Pregnant or lactating women.\n16. Presence of any severe or uncontrolled systemic disease.",{"count":290,"type":22},90,[292,122],"PHASE1","The purpose of this phase Ib\u002FII multicenter randomized control study is to investigate the efficacy and safety of peri-operative treatment with combination of CTLA-4, PD-1 antibodies and bevacizumab in resectable HCC",[295],"Resectable Hepatocellular Carcinoma",[297,298],"peri-operative treatment","hepatocellular carcinoma","2026-07-15",{"date":260,"type":33},{"date":260,"type":22},{"date":303,"type":22},"2030-05-31",{"name":39,"class":40},{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":92,"enrollmentInfo":312,"targetDuration":4,"studyType":23,"phases":314,"briefSummary":315,"conditions":316,"keywords":318,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":328},"100577323","phase-2-camrelizumab-combined-with-rivoceranib-and-hepatic-arterial-infusion-chemotherapy-haic-as-conversion-therapy-for-potentially-resectable-hepatocellular-carcinomahcc-100577323","NCT06796803","Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)","Camrelizumab and Rivoceranib Plus HAIC as Conversion Therapy for Potentially Resectable Intermediate-advanced Hepatocellular Carcinoma: a Multicenter, Open-label, Randomized, Phase 2\u002F3 Study","Inclusion Criteria:\n\n1. Signed Informed Consent Form (ICF)\n2. Aged ≥18 years and ≤75 years at time of signing ICF\n3. Documented diagnosis of HCC confirmed by histology\u002Fcytology or clinically\n4. Patients with BCLC stage B (the sum of number of tumors and the maximum diameter of the largest tumor exceeding Up-to-7 criteria) and BCLC stage C without extrahepatic metastasis: ① tumors confined to one lobe (left, right, or middle lobe), or tumors in one lobe are present alongside a single tumor with diameter ≤5 cm or up to three tumors each with diameter ≤3 cm in the remaining lobes; ②No PVTT involving the contralateral liver lobe or reaching the superior mesenteric vein. And no tumor thrombus of the inferior vena cava reaching right atrium\n5. Patients with recurrence following prior radical surgical resection must have undergone the initial surgery at least 5 years prior to study entry\n6. At least one measurable lesion (per RECIST v1.1) untreated lesion\n7. ECOG performance status of 0 or 1\n8. Child-Pugh ≤7 score\n9. Life expectancy ≥12 weeks\n10. Adequate organ function\n11. No prior anti-tumor systemic therapies for HCC\n\nExclusion Criteria:\n\n1. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC\n2. Other active malignant tumor except HCC within 5 years or simultaneously\n3. Prior locoregional therapy (such as TACE、TAE、HAIC、TARE)\n4. There is an absolute contraindication to HAIC\n5. History of hepatic encephalopathy\n6. Diffuse HCC, intrahepatic tumor burden \\> 50%\n7. PVTT reaching the superior mesenteric vein, and bilateral PVTT are present\n8. Clinically significant ascites\n9. Prior allogeneic stem cell or solid organ transplantation",{"count":313,"type":22},398,[122,96],"The purpose of this phase 2\u002F3 study is to investigate the efficacy and safety of camrelizumab combined with rivoceranib and hepatic arterial infusion chemotherapy (HAIC) as conversion therapy for Potentially Resectable HCC.",[317],"Potentially Resectable Hepatocellular Carcinoma",[319,298,320],"conversion therapy","camrelizumab and rivoceranib",{"date":322,"type":33},"2026-07-17",{"date":324,"type":33},"2025-02-20",{"date":326,"type":22},"2030-02-28",{"name":39,"class":40},2,{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":336,"targetDuration":338,"studyType":51,"phases":4,"briefSummary":339,"conditions":340,"keywords":344,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":4},"100646454","ai-driven-tumor-response-evaluation-for-solid-tumors-100646454","NCT07685548","AI-Driven Tumor Response Evaluation for Solid Tumors","Development of an Artificial Intelligence-Driven Novel Response Evaluation Framework and Its Biological Characterization","Inclusion Criteria:\n\n1. Age ≥ 18 years, any sex.\n2. Radiologically or pathologically confirmed diagnosis of solid tumor.\n3. Received non-surgical treatment with a clearly defined treatment start date.\n4. Availability of baseline and at least one follow-up imaging study (CT\u002FMRI) of sufficient quality for AI-based segmentation and volumetric analysis.\n5. Availability of key clinical data and follow-up outcome information.\n6. For retrospective cohort: prior signed informed consent for biobank donation, agreeing to donate samples and data for medical research.\n7. For prospective cohort: planned to receive or currently receiving non-surgical treatment, and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Imaging data incomplete or of insufficient quality for accurate segmentation or volumetric calculation.\n2. Key clinical information or follow-up outcome data missing.\n3. Treatment start or baseline time point cannot be clearly determined.\n4. Concurrent other malignancy that cannot be distinguished from the primary study tumor.\n5. Severe underlying diseases (e.g., cardiac, pulmonary, renal insufficiency) that may significantly affect survival outcome assessment.\n6. Cognitive impairment or other conditions that prevent cooperation with study procedures.\n7. For prospective cohort: expected inability to complete follow-up.\n8. Other conditions judged by the investigator as unsuitable for study inclusion. -",{"count":337,"type":22},6120,"36 Months","Purpose: This study is developing and validating an artificial intelligence (AI)-driven system to evaluate tumor response using changes in total tumor volume. The goal is to determine whether this AI-based approach can better predict patient survival compared with the current standard method (RECIST), which relies on linear measurements of a few selected tumors.\n\nParticipants: The study includes both retrospective and prospective cohorts. The retrospective cohort includes approximately 6,000 patients with solid tumors who received non-surgical treatment between 2015 and 2025. The prospective cohort will enroll approximately 120 patients starting in mid-2026.\n\nStudy details include:\n\nStudy Duration: Approximately 3 years\n\nParticipation Duration: Up to 6 months for prospective participants; retrospective participants contribute existing medical records only\n\nVisit Frequency: For prospective participants, follow-up visits occur every 3 months (up to 6 months) aligned with routine clinical care\n\nIntervention: None. This is an observational study using routine clinical imaging (CT\u002FMRI) and medical records\n\nPrimary endpoints: Overall survival (OS) and progression-free survival (PFS). The study will also evaluate the feasibility and impact of AI-assisted tumor response reporting on clinical workflow and patient understanding.\n\nParticipants in the prospective cohort will receive either a standard RECIST report or an AI-assisted dynamic tumor response report. This comparison is for research purposes only and does not alter standard medical care.",[341,342,343],"Solid Tumor Cancer","Neoplasms","Hepatocellular Carcinoma",[345,346],"Artificial Intelligence","Tumor Response Evaluation","2026-07-06",{"date":349,"type":33},"2026-07-08",{"date":351,"type":22},"2026-07-01",{"date":353,"type":22},"2029-06-30",{"name":39,"class":40},{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":23,"phases":364,"briefSummary":366,"conditions":367,"keywords":369,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":380},"100616563","phase-4-efficacy-and-safety-of-iglarlixi-versus-standard-of-care-in-a-real-world-adult-china-population-with-uncontrolled-type-2-diabetes-on-oral-agents-100616563","NCT07307235","Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents","Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents-a Pragmatic Randomized Controlled Trial","Inclusion Criteria:\n\n1. Participant must be at least 18 of age inclusive, at the time of signing the informed consent.\n2. Type 2 diabetes mellitus diagnosis.\n3. Participants who are treated for at least 3 months prior to the screening visit with an adequate dose of 1-3 OADs.\n4. HbA1c 7.5-11%\n5. Further intensification with an additional antidiabetic injectable medication is indicated to achieve glycaemic target at the discretion of the study physician according to approval labelling.\n\nParticipants who have signed informed consent form (ICF).\n\nExclusion Criteria:\n\n1. Diagnosed with T1DM\n2. BMI \\\u003C20 kg\u002Fm2 or BMI ≥40 kg\u002Fm2\n3. Treatment with more than 3 oral antidiabetic medications, or any injectable medication in a period of 30 days before the day of eligibility assessment. Temporary\u002Femergency use of insulin is allowed, as is prior insulin treatment for gestational diabetes.\n4. Contraindications to iGlarLixi according to the China NMPA approved label.\n5. Any clinically significant abnormality identified on physical examination, laboratory tests, or vital signs at the time of screening, or any major systemic disease resulting in short life expectancy that in the opinion of the Investigator would restrict or limit the patient's successful participation for the duration of the study.\n6. Participants who involved in other clinical trial within 3 months prior to the time of screening visit.\n7. Participant who has a severe renal function impairment with an estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m2\n8. Pregnant or breast-feeding woman.\n9. Woman of childbearing potential not protected by highly effective contraceptive method of birth control and\u002For who is unwilling or unable to be tested for pregnancy.\n10. Conditions\u002Fsituations such as:\n\nParticipant with short life expectancy. Participant with conditions\u002Fconcomitant diseases making him\u002Fher not evaluable for the primary efficacy endpoint (eg, hemoglobinopathy or hemolytic anemia, receipt of blood or plasma products within 3 months prior to screening).\n\nParticipant with conditions\u002Fconcomitant diseases precluding his\u002Fher safe participation in this study (eg, active malignant tumor, major systemic diseases, presence of clinically significant diabetic retinopathy or presence of macular edema likely to require laser treatment within the study period).\n\nUncooperative or any condition that could make the participant potentially non-compliant to the study procedures.",{"count":363,"type":22},1316,[365],"PHASE4","This study is a prospective, open-label, multicenter, parallel-group, positive-controlled, and pragmatic randomized clinical trial (pRCT). It will compare the efficacy and safety of iGlarLixi versus standard of care in adult T2DM patients with poor glycemic control, who are using 1 to 3 OADs in a real-world clinical practice setting. A total of 1,316 subjects from approximately 40 research centers in China will be randomly assigned in a 1:1 ratio to one of the following treatment groups: Group 1: iGlarLixi for blood glucose control; and Group 2: Standard of care for diabetes (basal insulin or premixed insulin, excluding any GLP-1RA-containing drugs). Considering the substantial difference in intervention methods between the two groups, the study is designed as non-blinded with an open-label approach.",[368],"Type 2 Diabetes",[370,371,372],"diabetes","iGlarLixi","RCT",{"date":374,"type":33},"2026-07-07",{"date":376,"type":33},"2025-12-13",{"date":378,"type":22},"2027-12-30",{"name":39,"class":40},24,{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":389,"conditions":390,"keywords":392,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":404,"locationsCount":41},"100636140","a-study-on-a-predictive-model-for-efficacy-and-prognosis-of-pancreatic-carcinoma-based-on-multimodal-data-100636140","NCT07561814","A Study on a Predictive Model for Efficacy and Prognosis of Pancreatic Carcinoma Based on Multimodal Data","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically or cytologically confirmed diagnosis of pancreatic cancer.\n* Availability of preoperative and postoperative contrast-enhanced CT images at the participating center; patient records include corresponding clinical data, postoperative pathological reports, and preoperative and postoperative blood test results.\n* Underwent surgical treatment for pancreatic cancer at a participating center of this study.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years (minors).\n* Presence of other severe diseases (e.g., severe liver or kidney failure, cardiovascular or cerebrovascular diseases, malignancies other than pancreatic cancer); pregnant or breastfeeding women; individuals with mental illness;\n* patients unable to comply with follow-up or provide informed consent.\n* Presence of significant outliers (e.g., laboratory values exceeding 10 times the normal range without clinically reasonable explanation) or samples with excessive missing data.",{"count":388,"type":22},1030,"The goal of this observational study is to learn if combining information from CT scans, blood tests, and pathology reports can better predict how pancreatic cancer will progress.\n\nThe main questions it aims to answer are:\n\n* Can combining these types of data more accurately estimate how long a person might survive?\n* Can it better predict the risk of recurrence?\n\nParticipants will not have any extra tests or treatments. They will:\n\n* Allow researchers to collect information from their existing medical records (such as surgery reports, imaging, and lab results)\n* Receive a follow-up phone call for up to 3 years to share health updates（about every 3 months for the prospective cohort）.",[391],"Pancreatic Cancer",[393,394,395,396,397,398],"Pancreatic cancer","Multimodal data","Deep learning","Predictive model","Prognosis","CT imaging",{"date":400,"type":33},"2026-07-02",{"date":402,"type":33},"2025-12-09",{"date":262,"type":22},{"name":39,"class":40},{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":412,"enrollmentInfo":413,"targetDuration":4,"studyType":23,"phases":415,"briefSummary":416,"conditions":417,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":424,"locationsCount":4},"100647027","phase-2-haic--deb-tace--toripalimab--lenvatinib-for-unresectable-intrahepatic-cholangiocarcinoma-100647027","NCT07685535","HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma","Hepatic Arterial Infusion Chemotherapy (HAIC) Sequential Small-Sized Drug-Eluting Beads Transarterial Chemoembolization (DEB-TACE) Combined With Toripalimab and Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma: A Phase II Clinical Study","Inclusion Criteria:\n\n1. Voluntary participation and signed informed consent.\n2. Age 18 to 85 years.\n3. Pathologically confirmed intrahepatic cholangiocarcinoma.\n4. Imaging-confirmed unresectable locally advanced intrahepatic cholangiocarcinoma with measurable lesions (longest diameter ≥10 mm) per RECIST 1.1.\n5. No distant organ metastases (excluding lymph node metastases).\n6. Child-Pugh liver function grade A or good B (≤7 points).\n7. ECOG performance status score 0-1 within 1 week before enrollment.\n8. Expected survival ≥12 weeks.\n9. No prior treatment with immune checkpoint inhibitors (including PD-1\u002FPD-L1 antibodies and CTLA-4 inhibitors).\n10. Laboratory values within 7 days before enrollment meeting the following criteria:\n\nANC ≥1.0×10⁹\u002FL; platelets ≥50×10⁹\u002FL; hemoglobin ≥90 g\u002FL (without transfusion or G-CSF within 14 days before screening).\n\nSerum albumin ≥30 g\u002FL; total bilirubin ≤1.5×ULN; ALT and AST ≤5×ULN; serum creatinine ≤1.5×ULN or CrCl \\>50 mL\u002Fmin (Cockcroft-Gault formula).\n\nINR ≤2.3 or PT prolonged ≤6 seconds above normal range.\n\nUrine protein \\\u003C2+ (if ≥2+, 24-hour quantification \\\u003C1.0 g allowed).\n\nExclusion Criteria:\n\n1. Received other local treatments (excluding surgery) within 1 month before study entry. Prior TAE\u002FTAI not allowed. Prior TACE \\>3 times not allowed.\n2. Prior systemic anti-tumor therapy (including targeted therapy, immunotherapy, chemotherapy).\n3. Concurrent or prior other malignancy within 5 years.\n4. Active autoimmune disease or history of autoimmune disease with potential relapse.\n5. Clinically symptomatic moderate-to-severe ascites requiring therapeutic paracentesis\u002Fdrainage or Child-Pugh score \\>2; uncontrolled or moderate-to-large pleural\u002Fpericardial effusion.\n6. History of abdominal fistula, GI perforation, or intra-abdominal abscess within 6 months before study treatment.\n7. History of thrombosis or embolic events (e.g., cerebrovascular accident including TIA, cerebral hemorrhage, cerebral infarction, pulmonary embolism) within 6 months before study treatment.\n8. Known inherited or acquired bleeding disorder or thrombotic tendency; currently or recently (within 10 days) receiving full-dose anticoagulants or thrombolytics for therapeutic purposes (prophylactic low-dose aspirin or LMWH allowed).\n9. Major vascular disease within 6 months before study treatment (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis).\n10. Severe, non-healing, or dehisced wounds, active ulcers, or untreated fractures.\n11. Major surgery within 4 weeks before study treatment (excluding diagnostic) or anticipated need for major surgery during the study.\n12. History of intestinal obstruction or clinical signs\u002Fsymptoms of GI obstruction within 6 months before study treatment.\n13. History of hepatic encephalopathy.\n14. Palliative radiotherapy for non-target lesions allowed only if completed ≥2 weeks before study treatment and AEs recovered to ≤CTCAE grade 1.\n15. Severe infection within 4 weeks before study treatment, including hospitalization for infection, bacteremia, or severe pneumonia; oral or IV therapeutic antibiotics within 2 weeks (prophylactic allowed).\n16. Congenital or acquired immunodeficiency (e.g., HIV infection).\n17. Palliative radiotherapy involving \\>5% of bone marrow area within 4 weeks for patients with bone metastases.\n18. Received live attenuated vaccine within 28 days before study treatment, or expected to receive such vaccine during toripalimab treatment or within 60 days after last dose.\n19. Received other investigational drugs within 28 days before study treatment.\n20. Other factors judged by the investigator that may affect study results or cause premature termination, such as alcoholism, drug abuse, other serious diseases (including psychiatric) requiring concomitant treatment, severe laboratory abnormalities, family or social factors affecting patient safety.","85 Years",{"count":414,"type":22},29,[122],"Purpose: This phase II clinical trial evaluates whether a combination of liver-directed local therapies (HAIC and DEB-TACE) with immunotherapy (toripalimab) and targeted therapy (lenvatinib) is safe and effective for patients with unresectable intrahepatic cholangiocarcinoma (a type of liver cancer that cannot be removed by surgery).\n\nParticipants: Adults aged 18-85 years with pathologically confirmed unresectable intrahepatic cholangiocarcinoma, no prior immune checkpoint inhibitor therapy, and adequate organ function.\n\nStudy details include:\n\nStudy Duration: Up to 24 months per participant\n\nTreatment Duration: Up to 6 cycles (each cycle is 21 days) of combination therapy, followed by maintenance therapy with toripalimab and lenvatinib until disease progression or unacceptable toxicity\n\nVisit Frequency: Every 3 weeks during the treatment phase; tumor imaging assessments every 6-8 weeks\n\nPrimary endpoints: Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Safety will be assessed by monitoring adverse events graded according to NCI-CTCAE v5.0.\n\nToripalimab and lenvatinib are not available through an expanded access program.",[418],"Liver Cancer","2026-06-28",{"date":347,"type":33},{"date":422,"type":22},"2026-06-30",{"date":156,"type":22},{"name":39,"class":40},{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":432,"targetDuration":4,"studyType":23,"phases":434,"briefSummary":435,"conditions":436,"keywords":438,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":445,"completionDateStruct":446,"leadSponsor":448,"locationsCount":41},"100645381","eit-guided-visual-feedback-during-incentive-spirometry-for-postoperative-atelectasis-100645381","NCT07681232","EIT-Guided Visual Feedback During Incentive Spirometry for Postoperative Atelectasis","Effects of Electrical Impedance Tomography-Guided Visual Feedback During Incentive Spirometry on the Immediate Ventilation Distribution in Postoperative Patients With Atelectasis: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Admitted to an intensive care unit or postoperative monitoring unit after major thoracic or upper-abdominal surgery; tracheal tube removed; spontaneously breathing; and clinically stable.\n3. Alert and able to understand and follow incentive-spirometry and EIT instructions.\n4. Bedside lung ultrasound shows atelectasis or markedly reduced aeration in dorsal or posterolateral lung regions, with the lung-ultrasound assessment recorded.\n5. Baseline EIT during quiet breathing in a semi-recumbent position shows insufficient dorsal ventilation with potential for improvement; dorsal ventilation fraction below 50%.\n6. Written informed consent provided by the participant or legally authorized representative according to the ethics-approved process, with participant re-consent when decision-making capacity returns.\n\nExclusion Criteria:\n\n1. Ongoing invasive mechanical ventilation or noninvasive ventilation, or high-flow nasal oxygen when study conditions cannot be maintained stably.\n2. Hemodynamic instability or inability to tolerate a semi-recumbent position.\n3. Inability to cooperate with training or impaired consciousness.\n4. Unsuitable for EIT monitoring, including an implanted pacemaker or defibrillator incompatible with the device, severe skin disease at the electrode-belt site, or known relevant allergy.\n5. Severe underlying pulmonary disease likely to substantially affect ventilation distribution and obscure the intervention effect.\n6. Chest-wall deformity or severe scoliosis affecting EIT image quality.\n7. Body mass index greater than 35 kg\u002Fm2.\n8. Pregnancy or breastfeeding.\n9. Current participation in another interventional clinical trial that could interfere with study outcomes.\n10. Any other condition that, in the investigator's judgment, makes participation inappropriate.",{"count":433,"type":22},60,[25],"This single-center randomized controlled trial will evaluate whether real-time visual feedback from electrical impedance tomography (EIT) improves the immediate distribution of lung ventilation during incentive spirometry in adults with postoperative atelectasis. Approximately 60 participants will be randomized 1:1 to receive either EIT-guided visual feedback or standardized verbal guidance during one session of 30 incentive-spirometry breaths. The primary outcome is the change in dorsal ventilation fraction from before training to 5 minutes after training. Secondary outcomes include inspiratory capacity, ventilation homogeneity, dependent silent spaces, end-expiratory lung impedance, oxygenation, in-hospital intubation or reintubation, and intervention-related adverse events.",[437],"Postoperative Atelectasis",[439,440,441,211,442],"Electrical Impedance Tomography","Incentive Spirometry","Visual Feedback","Dorsal Ventilation","2026-06-26",{"date":400,"type":33},{"date":351,"type":22},{"date":447,"type":22},"2027-12-31",{"name":39,"class":40},{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":71,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":456,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":458,"conditions":459,"keywords":462,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":469,"completionDateStruct":470,"leadSponsor":472,"locationsCount":41},"100644949","eye-tracking-for-early-identification-of-post-icu-cognitive-impairment-100644949","NCT07676864","Eye Tracking for Early Identification of Post-ICU Cognitive Impairment","Early Identification of Post-ICU Cognitive Impairment Using Eye-Tracking Technology: A Prospective Observational Study","Inclusion Criteria:\n\n* Successfully transferred from the ICU to a general ward after ICU treatment.\n* ICU length of stay of at least 24 hours.\n* Conscious and able to cooperate with cognitive assessment and eye-tracking tests.\n* Willing to participate in the study and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Diagnosed with cognitive impairment before ICU admission, such as Alzheimer's disease, based on medical history or previous medical records.\n* Previous diagnosis of mental illness or intellectual developmental disorder.\n* Severe visual, hearing, or eye disease that prevents completion of cognitive assessment or eye-tracking tasks.\n* Severe neurological disease that may affect cognitive function, such as stroke, traumatic brain injury, or intracranial infection.\n* Unable to understand or complete the cognitive assessment or eye-tracking tasks due to severe fatigue, marked inattention, communication disorder, or other reasons as assessed by the research staff.",{"count":457,"type":22},73,"Some patients may have problems with memory, attention, thinking speed, or other cognitive functions after leaving the intensive care unit (ICU). This is called post-ICU cognitive impairment. Early recognition of this problem may help clinicians provide follow-up care and support more promptly.\n\nThis study will explore whether eye-tracking technology can help identify cognitive impairment in patients soon after ICU discharge. Eye tracking is a non-invasive test that records eye movements while a person looks at images or completes simple visual tasks on a screen. The test does not involve any treatment or change in usual medical care.\n\nParticipants will be adult patients who have been transferred from the ICU to a general ward. Within 7 days after ICU discharge, participants will complete a cognitive assessment and an eye-tracking test. The study team will also collect relevant clinical information from medical records. Patients will be grouped according to whether they have post-ICU cognitive impairment based on cognitive assessment and clinical judgment.\n\nThe main purpose of this study is to assess whether information obtained from eye-tracking tests can help clinicians identify possible post-ICU cognitive impairment at an early stage, when used together with standard cognitive assessment. The study will also compare eye movement patterns between the two groups and explore whether eye-tracking measures add useful information beyond standard cognitive assessment.",[460,461],"Post Intensive Care Syndrome (PICS)","Cognitive Impairment",[463,461,464,465,466],"Eye Tracking","Cognitive Assessment","Intensive Care Unit","Post intensive Care Syndrome","2026-06-24",{"date":422,"type":33},{"date":279,"type":22},{"date":471,"type":22},"2027-05",{"name":39,"class":40},{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":479,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":481,"targetDuration":483,"studyType":51,"phases":4,"briefSummary":484,"conditions":485,"keywords":489,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":504,"locationsCount":505},"100633664","association-between-chronic-psychological-stress-and-disease-course-outcomes-in-pancreatic-cancer-100633664","NCT07529626","Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer","A Prospective Cohort Study on the Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer: A Comprehensive Analysis Based on Multidimensional Dynamic Psychological Assessment (MIND-PANC)","MIND-PANC","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically or cytologically confirmed diagnosis of pancreatic cancer, or other pancreatic diseases.\n* Conscious, with basic reading\u002Fwriting or communication skills, able to understand and complete the questionnaire assessments (either independently, with assistance from research staff, or with help from a family member).\n* Voluntarily agree to participate in this study and sign a written informed consent form.\n\nExclusion Criteria:\n\n* Presence of severe cognitive impairment (e.g., dementia, disturbance of consciousness) or a definite history of psychiatric disorders, judged by the investigator as unable to comply with the study assessments, and without a family member who can help complete the questionnaire assessments.\n* Presence of other severe, uncontrolled systemic diseases (e.g., severe heart, lung, or kidney failure), with an estimated life expectancy \\\u003C 3 months as judged by the investigator.\n* Inability to understand Chinese or presence of severe visual\u002Fhearing impairment that affects completion of the questionnaire assessments, and without a family member who can help complete the questionnaire assessments.",{"count":482,"type":22},320,"3 Years","This is a prospective, observational cohort study (MIND-PANC) to explore the associations of chronic psychological stress with disease progression, treatment outcomes, and prognosis of pancreatic cancer.\n\nResearchers will ask participants to fill out simple questionnaires about their mood, worries, and sleep at the start of the study and at regular follow-up visits. The study will also collect a small blood sample (leftover from routine care) to measure stress-related markers.\n\nInvestigators hypothesize that pancreatic cancer patients who have higher levels of ongoing psychological stress (such as anxiety, depression, or poor sleep) tend to have shorter survival times, a higher chance of recurrence, and a poorer response to treatment, compared to patients with lower stress levels.",[486,487,488],"Pancreatic Tumor, Benign","Pancreatic Cancer, Adult","Pancreatic Cancer Resectable",[490,491,492,493,494,495,496,497,498],"pancreatic cancer","anxiety","depression","psychological distress","Hospital Anxiety and Depression Scale","Pittsburgh Sleep Quality Index","disease progression","Overall survival","quality of life",{"date":500,"type":33},"2026-06-29",{"date":502,"type":33},"2026-05-11",{"date":156,"type":22},{"name":39,"class":40},3,{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":92,"enrollmentInfo":513,"targetDuration":4,"studyType":23,"phases":514,"briefSummary":515,"conditions":516,"keywords":518,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":523,"completionDateStruct":524,"leadSponsor":526,"locationsCount":4},"100644625","phase-2-a-randomized-double-blind-placebo-controlled-study-evaluating-the-effect-of-lae102-injection-in-combination-with-tirzepatide-on-body-in-obese-participants-100644625","NCT07671391","A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese Participants","A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body Composition in Obese Participants","Inclusion Criteria:\n\n1. Voluntarily participate in the study and sign the Informed Consent Form (ICF);\n2. Male or female participants aged between 18 and 75 years (inclusive) at the time of signing the ICF;\n3. BMI ranging from 28.0 to 40.0 kg\u002Fm2 during the screening;\n4. Self-reporting at least one experience of weight loss failure after adjusting diet and exercise, and within the previous 3 months, the weight change after only dietary and exercise adjustments was less than 5%;\n\nExclusion Criteria:\n\n1. A clear diagnosis of type 1, type 2 diabetes or other types of diabetes (excluding gestational diabetes);\n2. Screening criteria: Glycated hemoglobin ≥ 6.5% or fasting blood glucose ≥ 7.0 mmol\u002FL.\n\n   Obesity related:\n3. Diagnosed with secondary obesity;\n4. Previously underwent surgical or endoscopic weight loss metabolic surgery (except for local liposuction within 1 year before screening) or gastric balloon implantation, or planned to undergo any weight loss surgery or receive other weight loss treatments during the study;\n5. Uncontrolled thyroid disease, or screening criteria.",{"count":433,"type":22},[122],"This study is a randomized, double-blind, placebo-controlled trial aimed at exploring the effects of LAE102 injection in combination with Tirzepatide on body composition.",[517],"Obesity Adult Onset",[519,517,520],"LAE102 injection","Investigator-initiated trial","2026-06-22",{"date":443,"type":33},{"date":279,"type":22},{"date":525,"type":22},"2027-12",{"name":39,"class":40},{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":4,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":18,"minAge":145,"maxAge":4,"enrollmentInfo":534,"targetDuration":4,"studyType":23,"phases":536,"briefSummary":537,"conditions":538,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":542,"completionDateStruct":543,"leadSponsor":545,"locationsCount":41},"100640190","phase-4-ertugliflozins-effect-on-heart-function-in-diabetic-patients-after-myocardial-infarction-100640190","NCT07621380","Ertugliflozin's Effect on Heart Function in Diabetic Patients After Myocardial Infarction","Effect of Ertugliflozin on NT-proBNP and Cardiac Function After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Prospective, Randomized, Open-Label, Blinded Endpoint (PROBE) Trial","Inclusion Criteria:\n\n1. Adults aged 19 years or older\n2. Clinically confirmed type 2 diabetes mellitus (T2DM)\n3. First acute myocardial infarction (AMI) with planned randomization within 72 hours of AMI onset\n4. Ability to understand and voluntarily sign written informed consent\n\nExclusion Criteria:\n\n1. Type 1 diabetes mellitus or history of diabetic ketoacidosis\n2. Gestational diabetes, pregnancy, or breastfeeding\n3. End-stage renal disease (ESRD), dialysis, or prior kidney transplantation\n4. Use of any SGLT2 inhibitor within 4 weeks prior to enrollment\n5. Hemodynamic instability or investigator judgment that participation is not in the patient's best interest\n6. Systolic blood pressure \\\u003C 90 mmHg at enrollment or requiring vasopressors to maintain blood pressure",{"count":535,"type":22},476,[365],"This prospective, randomized, open-label, blinded endpoint (PROBE) trial evaluates the efficacy of early ertugliflozin initiation (10 mg daily) compared to standard care alone on cardiac function in 476 adult patients with type 2 diabetes mellitus (T2DM) following a first acute myocardial infarction (AMI). The study is supported by scientific rationale suggesting potential effects of ertugliflozin on cardiac resident macrophages in the heart after myocardial infarction.The primary objective is to assess the change in NT-proBNP levels from baseline to 26 weeks, while secondary endpoints explore echocardiographic parameters (such as LVEF and LAVi) and metabolic indices including blood ketone levels, HbA1c, and body weight. Eligible participants are randomized in a 1:1 ratio within 72 hours of AMI onset and followed for a total of 30 weeks to monitor both efficacy outcomes and safety events, with a specific focus on serious adverse events like severe hypoglycemia, genital infections, and ketoacidosis.",[539],"Type 2 Diabetes Mellitus Myocardial Infarction","2026-06-21",{"date":467,"type":33},{"date":351,"type":22},{"date":544,"type":22},"2028-03-01",{"name":39,"class":40},{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":552,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":556,"conditions":557,"keywords":558,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":570},"100644345","isatuximab-vrd-in-transplant-ineligible-newly-diagnosed-multiple-myeloma-patients-100644345","NCT07663253","Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients","A Single-Arm, Multicenter, Prospective, Observational Clinical Study on the Efficacy and Safety of Isatuximab Combined With Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Regimen in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TI-NDMM) Patients","CHAMPION-01","Inclusion Criteria:\n\n* Age ≥18 years\n* Newly diagnosed transplant-ineligible multiple myeloma patients as assessed by investigator, specifically referring to CSCO guidelines\n* Must meet corresponding laboratory test results (refer to restrictions in package inserts of combination drugs):\n\n  * Absolute neutrophil count (ANC) ≥1.0×10⁹\u002FL\n  * Platelet count ≥50×10⁹\u002FL\n  * Calculated creatinine clearance ≥30 mL\u002Fmin (using Cockcroft-Gault formula)\n  * Total bilirubin ≤3× upper limit of normal (ULN)\n* TI-NDMM patients intended for Isa-VRd regimen treatment as determined by investigator judgment, independent of study objectives Signed informed consent form (by patient or their legal representative)\n\nExclusion Criteria:\n\n* Patients currently participating in other interventional clinical studies\n* Patients with known severe hypersensitivity reactions to Isatuximab or any other excipients\n* Severe bacteremia at the time of administration\n* Currently uncontrolled cardiovascular disease, including:\n\n  * Uncontrolled hypertension\n  * Uncontrolled arrhythmia\n  * Uncontrollable congestive heart failure\n  * Unstable angina\n* Patients with peripheral neuropathy ≥Grade 2\n* Active infectious disease, known human immunodeficiency virus (HIV) positivity, active hepatitis B or hepatitis C\n* Patients who are currently pregnant\n* Patients who, at the physician's discretion, are unable to tolerate any drug in the combination regimen",{"count":555,"type":22},333,"Primary Objective of the trial is to evaluate the efficacy and safety of Isa-VRd-based regimen in transplant-ineligible newly diagnosed multiple myeloma (TI-NDMM) patients receiving treatment in real-world clinical practice in China.\n\nAnd Secondary Objectives is， To assess the MRD negativity rate in Chinese TI-NDMM patients treated with Isa-VRd To assess the safety and tolerability of Isa-VRd in Chinese TI-NDMM patients\n\nParticipants will:\n\nReceive Isatuximab 10 mg\u002Fkg iv\n\n* Cycle 1: Every weeks on Days 1, 8, 15, and 22\n* Cycles 2-8: Every 2 weeks on Days 1 and 15 Receive Bortezomib subcutaneous injection 1.3 mg\u002Fm²\n* Cycles 1-8: Days 1, 8, and 15 of each cycle Receive Lenalidomide oral 25 mg\u002Fday\n* Cycles 1-8: Days 1-21 at 25 mg\u002Fday (10 mg\u002Fday for patients with creatinine clearance \\[CrCl\\] ≥30 and \\\u003C60 mL\u002Fmin) Receive Dexamethasone oral 20 mg\n* Cycles 1-8: Days 1, 8, 15, and 22 of each cycle Following Cycle 8, the investigator may assess and adjust the treatment regimen During the induction phase, efficacy assessment is recommended at each treatment cycle. Patients who achieve ≥CR at the end of induction are recommended to undergo the first MRD monitoring assessment.\n\nDuring the maintenance phase, efficacy assessment is recommended at least every 3 cycles. Patients are recommended to undergo MRD status monitoring (≥CR) every 6 months (i.e., at months 14, 20, and 26) for MRD assessment.\n\nDuring the follow-up period, MRD status monitoring (≥CR) is recommended every 12 months to observe the depth of response.",[125],[559,560,561,125],"isatuximab","transplant-ineligible newly diagnosed multiple myeloma","TI NDMM","2026-06-17",{"date":564,"type":33},"2026-06-23",{"date":566,"type":22},"2026-06",{"date":568,"type":22},"2030-09",{"name":39,"class":40},13,{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":576,"acronym":577,"eligibilityCriteria":578,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":579,"targetDuration":4,"studyType":23,"phases":581,"briefSummary":582,"conditions":583,"keywords":586,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":41},"100641201","intravascular-ultrasound-guidance-versus-angiography-guidance-in-patients-with-st-segment-elevation-myocardial-infarction-100641201","NCT07616024","Intravascular Ultrasound guidaNce versuS angIoGrapHy Guidance in Patients With ST-segment Elevation Myocardial Infarction","Intravascular Ultrasound guidaNce versuS angIoGrapHy Guidance in Primary percuTaneous Coronary Intervention for Patients With ST-segment Elevation Myocardial Infarction","INSIGHT-STEMI","Inclusion criteria\n\n1. Patients diagnosed with acute ST-segment elevation myocardial infarction (STEMI) who have an indication for emergency interventional therapy;\n2. Subjects who are eligible to undergo primary percutaneous coronary intervention (PCI);\n3. Subjects or their authorized family members voluntarily agree to participate in the clinical trial and sign the written informed consent form;\n4. The IVUS catheter is expected to pass through the target lesion to complete the examination.\n\nExclusion Criteria\n\n1. Patients with cardiogenic shock or severe heart failure (Killip class IV);\n2. Patients who have previously undergone coronary artery bypass grafting (CABG);\n3. Patients with coma or disturbance of consciousness;\n4. Patients who are expected to be intolerant to long-term antiplatelet therapy;\n5. Pregnant women;\n6. Life expectancy \\\u003C 1 year;\n7. Currently participating in another drug\u002Fdevice clinical trial and not having reached the primary endpoint;\n8. Poor compliance, expected to be unable to complete follow-up.",{"count":580,"type":22},2488,[25],"STEMI represents the subtype of ACS with the worst prognosis, associated with high mortality and an elevated risk of complications. The use of IVI guidance holds the potential to reduce the incidence of MACE. In previous studies, there has been limited research on intravascular imaging in the context of primary revascularization procedures for STEMI, and no large-scale cohort study has compared the differences in clinical outcomes between IVI-guided and angiography-guided primary revascularization. Therefore, we conducted this large-scale randomized controlled trial to compare IVI-guided primary PCI versus coronary angiography-guided primary PCI in patients with STEMI.",[584,585],"STEMI","PCI",[584,585,587],"IVUS","2026-06-16",{"date":590,"type":33},"2026-06-18",{"date":592,"type":22},"2026-06-01",{"date":594,"type":22},"2032-12-31",{"name":39,"class":40},""]